Allist(688578)2024-04-25 10:36Financial Performance - The company's revenue for Q1 2024 reached ¥742,835,715.09, representing a year-on-year increase of 168.65%[4] - Net profit attributable to shareholders was ¥306,052,559.16, showing a significant increase of 777.51% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥301,141,732.04, reflecting a remarkable increase of 1,423.83% year-on-year[4] - Basic and diluted earnings per share were both ¥0.68, marking a substantial increase of 750.00% compared to the previous year[4] - The company achieved operating revenue of RMB 743 million in Q1 2024, a significant increase of 168.65% compared to the same period last year[12] - Net profit attributable to the parent company reached RMB 306.05 million, marking a substantial growth of 777.51% year-over-year[12] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 301.14 million, reflecting an impressive increase of 1,423.83% compared to the previous year[12] - Operating profit for Q1 2024 was CNY 313,917,428.44, compared to CNY 36,685,177.03 in Q1 2023, indicating a substantial increase of about 757.5%[19] - Net profit for Q1 2024 was CNY 306,052,559.16, up from CNY 34,877,411.06 in Q1 2023, reflecting an increase of approximately 775.5%[19] - The company reported a total comprehensive income of CNY 320,044,154.27 for Q1 2024, compared to CNY 34,174,103.40 in Q1 2023, indicating a growth of about 836.5%[19] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,376,495,351.66, an increase of 7.40% from the end of the previous year[4] - As of March 31, 2024, total assets amounted to RMB 4.70 billion, an increase from RMB 4.38 billion at the end of 2023[16][17] - The company's cash and cash equivalents stood at RMB 2.40 billion, up from RMB 1.86 billion at the end of 2023[16] - Total liabilities decreased to RMB 379.72 million from RMB 394.22 million at the end of 2023[17] - The equity attributable to the parent company increased to RMB 4.32 billion, compared to RMB 3.98 billion at the end of 2023[17] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 1,919,566,295.01, compared to CNY 374,809,250.57 at the end of Q1 2023, marking an increase of approximately 412.5%[22] Research and Development - Research and development expenses totaled ¥64,126,011.92, accounting for 8.63% of revenue, which is a decrease of 14.35 percentage points year-on-year[4] - Research and development expenses for Q1 2024 were CNY 64,126,011.92, slightly up from CNY 63,535,586.23 in Q1 2023, showing a marginal increase of 1%[18] - The company has received approval for the Phase I clinical trial of its self-developed KRAS G12D selective inhibitor, AST2169, which addresses a significant unmet clinical need[14] Shareholder Information - The top shareholder, Shanghai Qiaoke Enterprise Development Co., Ltd., holds 32.17% of the shares, with a total of 144,776,786 shares[9] - The company has a strong shareholder base, with the top 10 shareholders holding significant stakes, including Chen Xiaofa with 6,721,880 shares[11] Government Support - The company received government subsidies amounting to ¥1,325,609.20 during the reporting period[6] Product Performance - The increase in net profit was primarily driven by a substantial rise in sales of the drug Fumeitini, which was included in the medical insurance list this year[8] - The core product, Furmetin, has been included in the national medical insurance directory, which is expected to positively impact sales performance in 2024[13]